The short answer: yes, people switch from Ozempic (semaglutide) to Mounjaro or Zepbound (both tirzepatide) every day. The FDA labels for both tirzepatide products give one starting dose, 2.5 mg once weekly for four weeks, with no exception for people already on a GLP-1. Neither label describes a washout period, so the timing of your last Ozempic dose and first tirzepatide dose is your prescriber's decision. Expect the first month on 2.5 mg to feel weaker than your Ozempic maintenance dose, and expect some early nausea to return during titration.

Our sibling site covers the transition from the tirzepatide side in switching from Ozempic to Mounjaro. This article starts from where you are: on Ozempic, deciding whether the move is worth it.

Why do people switch from Ozempic to tirzepatide?

  • A stalled scale. Ozempic tops out at 2 mg, and many people stop losing somewhere between 0.5 mg and 1 mg. Our guide to the Ozempic plateau explains why. Tirzepatide offers more headroom, up to 15 mg, plus a second mechanism through the GIP receptor.
  • Head-to-head data. A randomized trial now compares the two drugs directly, and tirzepatide won on weight. The numbers are below.
  • Coverage or supply. A formulary change or a pharmacy that cannot fill Ozempic can force the issue regardless of how well the drug works.

One reason that does not hold up: side effects. Tirzepatide is not the gentler drug.

What did the head-to-head trial find?

SURMOUNT-5, published in the New England Journal of Medicine in July 2025, randomized 751 adults with obesity and no diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. The semaglutide arm used Wegovy doses, above the 2 mg Ozempic ceiling.

  • Mean weight change: tirzepatide -20.2% versus semaglutide -13.7%, a difference of 6.5 percentage points (95% CI -8.1 to -4.9).
  • In kilograms: 22.8 kg versus 15.0 kg.
  • Waist circumference: -18.4 cm versus -13.0 cm.
  • At least 25% of body weight lost: about 32% of the tirzepatide group versus about 16% of the semaglutide group.

Tolerability went the other way from what many expect. Discontinuation because of gastrointestinal events was 2.7% on tirzepatide and 5.6% on semaglutide; serious adverse events were 4.8% versus 3.5% (full results coverage). The trial was open-label.

Two caveats for an Ozempic user. Participants did not have diabetes, and nobody switched drugs. SURMOUNT-5 shows how the drugs compare from a standing start, not how much more you will lose after switching. Our Ozempic vs Mounjaro page covers the diabetes trials too.

Mounjaro or Zepbound: which one would you switch to?

Both pens contain tirzepatide at the same six strengths. The difference is the FDA indication, which determines what insurance will pay for.

  • Mounjaro is indicated to improve glycemic control in type 2 diabetes, in adults and children 10 and older, alongside diet and exercise.
  • Zepbound is indicated for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity.

Ozempic itself is labeled only for type 2 diabetes. If you take it for diabetes, Mounjaro is the like-for-like replacement. If you take Ozempic off-label for weight, Zepbound has the matching indication, and a plan that excludes weight-loss drugs will likely exclude it too.

What dose do you start at?

Both labels say the same thing, and neither makes an exception for people coming off another GLP-1 drug.

The Mounjaro label states a starting dosage of 2.5 mg once weekly, an increase to 5 mg after four weeks, and further increases in 2.5 mg steps after at least four weeks on the current dose, to a maximum of 15 mg. The Zepbound label uses the same 2.5 mg start and the same steps, with maintenance doses of 5 mg, 10 mg or 15 mg for weight, and 10 mg or 15 mg for sleep apnea.

So if you are on 1 mg or 2 mg of Ozempic, the label path still begins at 2.5 mg of tirzepatide, and that first month will likely feel like a step down in appetite control. Any decision to move through the steps faster is a prescriber's off-label call. A 2025 Korean series of 15 people with type 2 diabetes who switched from semaglutide to tirzepatide all started at 2.5 mg; those escalated to 10 mg within three months saw HbA1c fall 0.7 points, while those held at 7.5 mg saw no meaningful change. That is a signal, not a rule.

Do you need a washout before the first tirzepatide dose?

The labels do not say. What they do say is relevant.

The Ozempic label gives semaglutide an elimination half-life of about one week and notes the drug stays in circulation for about five weeks after the last dose. The Mounjaro label gives tirzepatide a half-life of about five days, with steady state after four weeks of weekly dosing. The Zepbound label adds that coadministration with any GLP-1 receptor agonist is not recommended.

Whatever day you inject your first 2.5 mg of tirzepatide, semaglutide will still be in your body for weeks. A one-week gap does not produce a clean washout; it only avoids two injections in the same week. Some prescribers start tirzepatide on the day the next Ozempic dose was due; others build in a week or two. Neither approach has a label behind it, and no randomized trial has compared them. The closest trial evidence, SURPASS-SWITCH, moved people from dulaglutide, a different weekly GLP-1, to tirzepatide starting at 2.5 mg. At 40 weeks it found larger reductions than escalating dulaglutide: HbA1c -1.44 versus -0.67 points, weight -10.5 kg versus -3.6 kg. Your prescriber sets the timing.

If you have diabetes, check glucose through the transition; the 2.5 mg dose lowers glucose less than the Ozempic dose you left.

Will the side effects come back?

Probably some of them, mostly at each dose step. The Mounjaro label lists nausea in 12% to 18% of patients across the 5 mg to 15 mg doses, diarrhea in 12% to 17%, vomiting in 5% to 9% and constipation in 6% to 7%. The Zepbound label, drawn from weight-management trials, lists higher rates: nausea 25% to 29%, diarrhea 19% to 23%, vomiting 8% to 13% and constipation 11% to 17%. Those are new-start figures; nobody has measured side effects in switchers in a controlled way.

The strategies that helped on Ozempic still apply: smaller meals, less fat, more fluid, and holding at a dose if the last step was rough. See our guide to managing Ozempic nausea. The four-week rhythm in our Ozempic dosing schedule is the same one tirzepatide uses.

What will it cost?

A switch can raise your monthly bill even though both drugs got cheaper.

For someone paying cash on 1 mg Ozempic at $349, a tirzepatide maintenance dose means $449 to $499 a month, a $100 to $150 increase. Insured patients need a new prior authorization; the criteria for Mounjaro (a diabetes diagnosis) and Zepbound (BMI thresholds or sleep apnea) differ from whatever approved your Ozempic. Our Ozempic cost guide covers the semaglutide savings programs.

The bottom line

Switching from Ozempic to tirzepatide is reasonable if you have plateaued, need a diagnosis-matched product, or lost coverage. SURMOUNT-5 favored tirzepatide by 6.5 percentage points of body weight over 72 weeks, with fewer gastrointestinal dropouts, though it studied neither switchers nor people with diabetes.

The labels give you a fixed start: 2.5 mg weekly for four weeks, then 2.5 mg steps at least four weeks apart, whatever dose of Ozempic you left. They give no washout rule, so your prescriber decides when the first tirzepatide injection happens. Plan for a weaker first month, some returning nausea at each step, a new prior authorization, and a likely rise in cash cost. If Ozempic is working and tolerated, staying put is also a defensible choice.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Do not stop, start, or change a prescribed medication without speaking to your prescriber. Dosing and timing decisions for a medication switch belong to the clinician who knows your history.